The Scandinavian Sarcoma Group skeletal metastasis register: Survival after surgery for bone metastases in the pelvis and extremities


Published in:
Acta Orthopaedica Scandinavica. Supplementum

DOI:
10.1080/00016470410001708270

2004

Link to publication

Citation for published version (APA):

Total number of authors:
10

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
The Scandinavian Sarcoma Group skeletal metastasis register

Survival after surgery for bone metastases in the pelvis and extremities

B. H. Hansen¹, J. Keller¹, M. Laitinen³, P. Berg⁴, S. Skjeldal⁵, C. Trovik⁶, J. Nilsson⁷, A. Walloe⁸, A. Kalén⁹ and R. Wedin²

Introduction  The assessment of the prognosis for the individual patient is important for the choice of surgical treatment of skeletal metastases. In 1999 the Scandinavian Sarcoma Group (SSG) initiated the Skeletal Metastasis Register as a multicentric, prospective study to provide a scientific basis for treatment recommendations. To improve prognostication we analyzed the survival of patients with skeletal metastases surgically treated at 9 SSG centres.

Patients and methods 460 patients with an average age of 64 years underwent 501 operations for non-spinal skeletal metastases. 7% were operated for more than one metastasis. Carcinoma of the breast, prostate, kidney and lung were the dominating primary tumors.

Results The survival rate was 0.4 at 1 year, 0.3 at 2 years and 0.2 at 3 years. Univariate analysis showed that survival was related to bone localization, skeletal metastatic load, presence of visceral metastases, Karnofsky performance score, primary tumor type, presence of a complete pathological fracture and preoperative hemoglobin content. Multivariate regression analysis showed that pathological fracture, visceral metastases, haemoglobin content < 7 mmol/L and lung cancer were negative prognostic factors for survival. Myeloma was the sole positive prognostic factor for survival.

During recent years, more attention has been directed towards improving palliative care for cancer patients with skeletal metastases. The aim of surgical treatment is to remove pain and maintain function for improved quality of life. Current operative treatment recommendations are mainly based on retrospective studies of single institutions (Yazawa et al. 1990, Bono et al. 1991, Yamashita et al. 1993, Smith et al. 1997, Dürr et al. 1998 and 2002, Wedin et al. 1999), but these patient series are often small and collected during a long period of time. Most studies deal with either bone metastasis in the spine or bone metastasis in the extremities due to differences in morbidity and treatment. SSG has since 1986 maintained a sarcoma register and in 1999 the Skeletal Metastasis Register was started with prospective registration of patients operated for skeletal metastases in the long bones and pelvis. In this first report we analyse possible prognostic factors affecting survival in a group of patients surgically treated in 9 SSG centres (Table 1).

Patients and methods

Criteria for inclusion were operation for bone metastases, myeloma or lymphoma in the extremities or pelvis. Between September, 1999 and
March, 2003, 474 patients underwent 515 operations and were followed prospectively. 14 patients were excluded because of missing data. There were 253 (55%) women and 207 (45%) men with a median age of 64 (11–96) years. The patients were registrated at operation and followed until November 2003 or death. In patients treated for more than one metastasis, survival was assessed from the time of the first operation. Carcinoma of the breast, prostate, kidney and lung were the most common primary tumor (Table 2). 69% of the patients had more than one known bone metastasis at the time of the first surgical procedure and 32% had known visceral metastases. The indication for surgery was a complete pathological fracture in 71%, impending fracture in 18% and pain in 11%. The functional ability was assessed with the Karnofsky (1967) score as good, moderate or poor performance. Operations concerned femur in 62%, humerus in 18%, pelvis in 12% and other locations in 8%. 206 (45%) patients were treated with prosthetic procedures and 239 (52%) with internal fixation. 46 (10%) patients had complications, mainly wound infection or prosthetic dislocation. 7% of the patients had reoperation related to the first surgically treated bone metastasis.

Statistics

Survival rates after surgery were estimated with the Kaplan-Meier method. The univariate log-rank test was used to evaluate the prognostic significance of individual factors. The Cox multiple regression analysis was used to assess the prognostic influence of different clinical features for 1-year survival.

Results

348/460 (76%) patients have died. 19% of the patients died within the first 6 weeks after operation and 44% within the first 6 months. The 1-year survival rate for the 460 patients was 0.39 (Figure 1). Age at surgery, sex and operation method was not related to survival.

Univariate analysis showed that 1-year survival was related to bone localization, skeletal metastatic load, presence of visceral metastases, Karnofsky performance score, primary tumor, presence of pathological fracture and preoperative hemoglobin content (Table 2). Patients with a solitary skeletal metastasis had the highest survival rate while patients with visceral metastases had the lowest. Patients with myeloma, lymphoma, and breast or kidney cancer had high survival rates at 1 year, while those with prostate, lung or unknown cancer had the lowest.

Multivariate regression analysis was based on the clinical factors found to be prognostic for 1-year survival at univariate analysis. The analysis selected pathological fracture, presence of visceral metastasis, hemoglobin < 7 mmol/L and lung cancer as independent negative prognostic factors for survival. Myeloma was a positive prognostic factor (Table 3). Excluding preoperative hemoglobin content from the multivariate analysis, good Karnofsky score was a positive factor (p = 0.003).

Discussion

In most studies of metastatic bone disease, including our, the prognosis is poor, 1-year survival is 0.30 to 0.54; in our study 0.39 (Bono et al. 1991, Bauer et al. 1995, Dürr et al. 1998, Bohm et al. 2002). The differences can be explained by patient selection, type of primary tumor and indications for surgery.

Operation of a pathological fracture in the femur gives immediate reduction in pain, facilitates patient nursing and reestablishes walking function. Patients operated for bone metastases of the pelvis, almost exclusively the acetabular area, had a tendency of longer survival than those operated for metastases in the femur. Such patients are selected since they pose less urgent demands for surgical...
treatment than patients with a pathological fracture in femur (Table 2).

It has been found that patients with myeloma, lymphoma, kidney and breast cancer have a better prognosis (Smith et al. 1992, Bauer et al. 1995, Althausen et al. 1997, Dürr et al. 1997, 1998, 1999, 2002), but in our series only myeloma was statistically significant in the univariate as well as the multivariate analysis. Our study support previous findings that lung cancer patients have a poor prognosis (Bauer et al. 1995, Dürr 1998). Prostate cancer has earlier been found to be either a positive (Bohm et al. 2002) or negative prognostic factor (Bauer et al. 1995). The reason may be that a higher proportion of hormone-refractory patients leads to lower survival rates. In our study prostate cancer was a negative prognostic factor in the univariate analysis, but not in the multivariate analysis.

Our study confirms that a complete pathological fracture and known visceral metastases are independent negative prognostic factors. (Bauer et al. 1995, Rex et al. 2000, Bohm et al. 2002, Dürr et al. 2002). Solitary skeletal metastasis was a positive prognostic factor in the univariate analysis, but was not an independent factor in the multivariate analysis as in the series of Bauer et al. (1995).

Only few authors have addressed performance and general health as prognostic factors. Patients with poor performance score have been shown to have a shorter survival as compared to patients with a good score (Tokuhashi 1991, Matzkin et al. 1993, Rex et al. 2000). In our study Karnofsky score was an independent factor first after excluding preoperative hemoglobin content from the multivariate analysis.

Hemoglobin has been used as a prognostic factor in metastatic prostate cancer (Matzkin et al. 1993). We found that preoperative anemia (< 7 mmol/L) was a strong negative prognostic factor in this heterogeneous group of cancer patients.

In the multivariate analysis we found the following negative factors: pathologi-

Table 2. Univariate analysis of 1-year survival rates according to various clinical factors in the 460 operated patients

<table>
<thead>
<tr>
<th>Factors</th>
<th>Number of patients</th>
<th>Survival rate</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at surgery:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–65</td>
<td>229 (50%)</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>&gt;65</td>
<td>231 (50%)</td>
<td>0.34</td>
<td></td>
</tr>
<tr>
<td>Sex:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>253 (55%)</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>207 (45%)</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Metastatic load</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solitary skeletal</td>
<td>95 (21%)</td>
<td>0.53 &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Multiple skeletal</td>
<td>317 (69%)</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>Unknown skeletal</td>
<td>48 (10%)</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>No visceral metastases</td>
<td>225 (49%)</td>
<td>0.46</td>
<td></td>
</tr>
<tr>
<td>Visceral metastases</td>
<td>146 (32%)</td>
<td>0.27 &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Unknown visceral</td>
<td>89 (19%)</td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td>Primary tumor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloma</td>
<td>32 (7%)</td>
<td>0.65 0.002</td>
<td></td>
</tr>
<tr>
<td>Lymphoma</td>
<td>14 (3%)</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>142 (31%)</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>56 (12%)</td>
<td>0.43</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>60 (13%)</td>
<td>0.34</td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td>70 (15%)</td>
<td>0.26 0.02</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>49 (11%)</td>
<td>0.24 0.009</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>37 (8%)</td>
<td>0.17 &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Pathologic fracture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>133 (29%)</td>
<td>0.47 0.007</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>327 (71%)</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>Localisation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>18 (4%)</td>
<td>0.72 0.01</td>
<td></td>
</tr>
<tr>
<td>Tibia</td>
<td>20 (4%)</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Pelvis</td>
<td>53 (12%)</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>Femur</td>
<td>285 (62%)</td>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>Humerus</td>
<td>84 (18%)</td>
<td>0.34</td>
<td></td>
</tr>
<tr>
<td>Karnofsky score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good</td>
<td>84 (18%)</td>
<td>0.55 0.002</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>263 (57%)</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>Poor</td>
<td>108 (24%)</td>
<td>0.25 0.002</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>5 (1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operation method</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Internal fixation</td>
<td>239 (52%)</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td>Prosthesis</td>
<td>207 (45%)</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>14 (3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin preoperative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 7 mmol/L</td>
<td>118 (26%)</td>
<td>0.22 &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>&gt;7 mmol/L</td>
<td>154 (33%)</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>188 (41%)</td>
<td>0.41</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Multivariate analysis of prognostic factors for survival

<table>
<thead>
<tr>
<th>Factors</th>
<th>Coefficient</th>
<th>SD</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pathologic fracture</td>
<td>0.20</td>
<td>0.09</td>
<td>0.03</td>
</tr>
<tr>
<td>Visceral metastases</td>
<td>0.35</td>
<td>0.17</td>
<td>0.04</td>
</tr>
<tr>
<td>Hemoglobin &lt;7mmol/L</td>
<td>0.50</td>
<td>0.16</td>
<td>0.002</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>0.66</td>
<td>0.26</td>
<td>0.01</td>
</tr>
<tr>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myeloma</td>
<td>-0.95</td>
<td>0.40</td>
<td>0.02</td>
</tr>
</tbody>
</table>
cal fracture, visceral metastasis, lung cancer, low hemoglobin and only one positive: myeloma. In the clinical practice it is of importance to identify patients with a very short survival and also patients with an exceptionally long survival. Most patients with 2 or 3 negative independent prognostic factors have an extremely short survival, whereas patients with no negative prognostic features may have a good prognosis. As a consequence, surgical procedures and reconstruction should be chosen that minimize the risk of long term failure in patients with a good prognosis and be as simple as possible in patients with a poor prognosis.

Evy Nilsson at the Scandinavian Sarcoma Group Secretariat in Lund, Sweden helped with collection of the clinical data.


